Today, Eli Lilly and Company (NYSE: LLY) launched a searchable clinical trial mobile application for oncology healthcare professionals. The app – available for Apple iPad and iPhone, as well as RIM's BlackBerry and Google's Android platforms – allows healthcare professionals to search oncology trials that are enrolling new patients by disease state, molecule being studied, study phase, country, state and keyword.
Because the mobile app provides details on all global oncology trials, the app's functionality also provides a mechanism for the healthcare professional to contact Lilly Oncology for additional details on its trials, as well as a third-party contact for the non-Lilly clinical trials.
"Lilly Oncology created the Clinical Trial Resource mobile app to offer cancer care professionals an easy way to search for and identify details about all global oncology clinical trials – not just those sponsored by Lilly," said Anne White, senior director of portfolio management with Lilly Oncology. "The information will enable physicians to provide the most current study information – quickly – to patients who may be interested in participating in a clinical trial."
Clinical trial app available on new Lilly Oncology websiteDirections for downloading the clinical trial app are available on a new website, LillyOncologyPipeline.com, an online resource that will house information on its pipeline of potential cancer and supportive care molecules. At LillyOncologyPipeline.com, healthcare professionals can search for information about Lilly Oncology's pipeline by drug discovery platform, cancer type, clinical trial phase and molecular target. Specific information about each medicine includes illustrations of the target pathway and, when available, video of the pipeline compound's method of action.
"With LillyOncologyPipeline.com, the healthcare professional will now have immediate access to detailed information on our diverse oncology pipeline," added White. "We hope that this will foster not only greater awareness of our potential medicines, but also spark innovative collaborations that ultimately change the world of cancer care."